Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I).

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

Abstract: The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SARMI within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARMI).